Excuses running thin

Discussion in 'Allergan' started by anonymous, Mar 7, 2019 at 8:22 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Allergan announced on Wednesday that rapastinel, its depression treatment, had failed to meet clinical goals in three late-stage trials, spurring concerns among analysts over the drugmaker's pipeline of products.

    "With this latest fiasco, we again call on the Company to install an independent chairman with suitable experience to bring new leadership to the Board and rein in management's predilection for value-destruction," Appaloosa said.

    The hedge fund, led by billionaire David Tepper, has also said Allergan should consider selling or separating itself, and demanded that it split the role of chairman and chief executive officer.

    Implementing Appaloosa's recommendations would be "highly disruptive" to its operations, Allergan has said.

    "The Board's misplaced fear of 'disrupting' Allergan is wearing thin as an excuse for inaction and can only perpetuate further erosion in the shareholders' investment," Appaloosa added on Thursday.
     

  2. anonymous

    anonymous Guest


    What this doesn’t mention is that our fearless leaders buried the first failures of rapastinel. Yes, they had indications long ago that this was going to flop.

    THESE GUYS ARE ABSOLUTE TOAST. ALREADY YESTERDAYS NEWS.

    Adios Brent, Bill and anyone else that carried their bucket.
     
  3. anonymous

    anonymous Guest

    When your stock is on an 8% upward run because investors think/hope it will be split up and sold off.... you have a serious problem.